AXL Inhibition Improves BRAF-Targeted Treatment in Melanoma

By
Justin.choi
-
0
20
The authors investigated the therapeutic potential of the AXL inhibitor BGB324 alone or in combination with the clinically relevant BRAF inhibitor vemurafenib.
[Scientific Reports]
Full Article